Sponsors (7)
The bill channels federal support and funding to build shared bioindustrial scale‑up facilities that can speed commercialization, create regional jobs, and strengthen supply chains, while trading off taxpayer expense, potential crowding‑out of other priorities, tensions with private IP incentives, and biosecurity/data‑sharing risks that will require careful governance.
Scientists, small biotech companies, and startups gain reliable access to pilot and scale‑up facilities and support that lower technical risk and improve prospects for attracting private investment and commercializing new bioindustrial products.
Workers, students, and regional economies gain new job and workforce-development opportunities as geographically distributed facilities expand U.S. biomanufacturing capacity and help retain manufacturing-related jobs domestically.
Researchers, industry, and small firms benefit from shared infrastructure and open data/access that lower costs, reduce duplication, and speed commercialization of technologies.
The open-access and broad data/IP requirements could raise biosecurity and data‑sharing risks if governance and safeguards are not strict, potentially endangering public health or sensitive information.
Making federally created IP public or imposing open‑access rules may discourage some private partners, reduce incentives for exclusive investment, and complicate traditional licensing models.
Taxpayers are exposed to up to $225.5 million in authorized federal spending over FY2026–2030 to construct and operate facilities.
Based on analysis of 3 sections of legislative text.
Directs DOE to create at least two open‑access bioindustrial technology maturation facilities by Sept 30, 2030 and expands Bioenergy program definitions to cover bioindustrial activities.
Introduced March 16, 2026 by James Baird · Last progress March 16, 2026
Requires the Department of Energy to create at least two open‑access bioindustrial technology maturation facilities by September 30, 2030, and expands the Bioenergy program’s legal definitions to cover industrial biotechnology, biointermediates (including products derived from biomass, waste, and carbon oxides), biomanufacturing, and related terms. The facilities must operate as user resources for government and nongovernment users to support precommercial R&D, demonstration, and activities that de‑risk product and process technologies relevant to DOE’s mission.